Analysis Of Income And Expense [Abstract]

ERYTECH Pharma S.A. - Filing #2810992

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Analysis of income and expense [abstract]
Material income and expense [abstract]
Research and development expense	—	10 910 EUR	—	—	—	—	—	—	—	19 907 EUR	—	—	—	—	—	—	—	45 100 EUR
Finance income (cost)	—	37,000 EUR	—	—	—	—	—	—	—	3 089 EUR	—	—	—	—	—	—	—	2 720 EUR
Selling, general and administrative expense [abstract]
General and administrative expense	—	14 076 EUR	—	—	—	—	—	—	—	13 887 EUR	—	—	—	—	—	—	—	15 595 EUR
Revenue and other operating income	—	1 326 EUR	—	—	—	—	—	—	—	30 998 EUR	—	—	—	—	—	—	—	4 180 EUR
Operating expense	—	24 986 EUR	—	—	—	—	—	—	—	33 794 EUR	—	—	—	—	—	—	—	60 695 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	213,000 EUR	—	—	—	—	—	—	—	187,000 EUR	—	—	—	—	—	—	—	528,000 EUR
Income tax relating to components of other comprehensive income [abstract]
Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss	—	— EUR	—	—	—	—	—	—	—	— EUR	—	—	—	—	—	—	—	— EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	— EUR	23 652 EUR	23 488 EUR	— EUR	49,000 EUR	213,000 EUR	235,000 EUR	— EUR	228,000 EUR	194,000 EUR	— EUR	187,000 EUR	53 797 EUR	— EUR	68,000 EUR	528,000 EUR	— EUR	54 257 EUR